Virax Biolabs Group Limited Ordinary Shares

NASDAQ VRAX
$0.57 -0.04 -6.87%
Today share price
USA
Sector: Healthcare Industry: Biotechnology
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Index: 15 %
Market cap Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.
4.95M
EV Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
720.89K
Beta Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
-
Shares Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
4.34M
YTD Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
-74.89 %

Upcoming events Virax Biolabs Group Limited Ordinary Shares

All events
No upcoming events scheduled

Stock chart Virax Biolabs Group Limited Ordinary Shares

Stock analysis Virax Biolabs Group Limited Ordinary Shares

Indicator Company Industry
P/E (LTM) Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.
-0.75 -1.30
P/BV (LTM) Shows the ratio of the market price of the share to the current book value.
0.84 1.15
EV/EBITDA (LTM) Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.
-0.11 -0.75
Net Debt/EBITDA (LTM) A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.
0.65 0.42
ROE (LTM) Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.
-115.52 -50.00

Price change Virax Biolabs Group Limited Ordinary Shares per year

0.57$ 3.19$
Min Max

Summary analysis Virax Biolabs Group Limited Ordinary Shares

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure Virax Biolabs Group Limited Ordinary Shares

Revenue and net income Virax Biolabs Group Limited Ordinary Shares

All parameters

About company Virax Biolabs Group Limited Ordinary Shares

Virax Biolabs Group Limited, a biotechnology company, distributes, markets, and sells diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name. It also develops T-Cell IVD test kit for COVID-19, which intend to adapt for immunological profiling against multiple viral threats under the ViraxImmune Brand, as well as a proprietary mobile application for ViraxImmune that presents an individual's immunological profiling data and provide advice on the users' immune system. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, pharmaceutical companies, research institutions, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was founded in 2013 and is headquartered in Lanarkshire, the United Kingdom.
Address:
BioCity Glasgow, Lanarkshire, United Kingdom, ML1 5UH
Company name: Virax Biolabs Group Limited Ordinary Shares
Issuer ticker: VRAX
Country: USA
Exchange: NASDAQ
Currency: $
IPO date: 2022-07-21
Sector: Healthcare
Industry: Biotechnology
Site: https://viraxbiolabs.com